Exact Sciences stock holds recent gains after summer results

Published on 09/14/2026 at 19:20 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Exact Sciences stock closed at USD 66.40 on the Nasdaq on September 11, 2026, modestly above the prior day’s level. The move follows the company’s latest quarterly report, with investors watching revenue trends and margins into the autumn.

Exact Sciences, US30063P1057, Illustration mit AI erstellt.

Exact Sciences stock (ISIN US30063P1057) finished the last completed session on the Nasdaq at USD 66.40 on September 11, 2026, marking a 1.2% gain versus the previous close in a day of mixed broader indices.

Stock consolidates after recent move

According to Ad-hoc-news on September 14, 2026, Exact Sciences stock closed at USD 66.40 on September 11, 2026 after trading between an intraday low near USD 65.10 and a high around USD 67.20, leaving the shares comfortably within their 52-week range.

The same overview notes that the 1.2% advance on September 11, 2026 slightly outpaced the modest percentage moves recorded by major US indices such as the S&P 500 and the Nasdaq Composite, underscoring a degree of relative strength in Exact Sciences compared with large-cap benchmarks.

Revenue growth and margins remain in focus

In its most recent quarterly report for Q2 2026, Exact Sciences reported year-over-year revenue growth in its core diagnostic businesses, with investors paying particular attention to how adjusted EBITDA and gross margin trends set the tone for the second half of the year; this latest interim period lies well within the current reporting window and anchors many of the fundamental discussions around the stock.

Historical context also matters for many shareholders: in fiscal year 2024, revenue and operating metrics provided a baseline against which the Q2 2026 figures are being compared, with the more recent quarter showing a clear improvement in topline trends versus earlier years, even as profitability measures continue to be scrutinized in detail.

Analyst views and valuation backdrop

Analyst coverage of Exact Sciences stock continues to emphasize the balance between growth potential in cancer screening and the need to reach sustained profitability, with ratings and price targets framed around the company’s ability to expand test volumes while managing operating expenses.

Against this backdrop, valuation discussions often refer to the current share price region around the mid-60s in USD as of September 11, 2026 in relation to historical trading ranges and implied multiples on consensus revenue expectations, making the recent 1.2% move a relatively modest adjustment rather than a major re-rating.

Exact Sciences stock price snapshot

As of September 11, 2026, Exact Sciences stock closed at USD 66.40 on the Nasdaq, with the intraday range between roughly USD 65.10 and USD 67.20 illustrating a day of steady trading interest and a price level that remains below the upper end of the 52-week band but clearly above the lows for the period.